Madrigal Pharmaceuticals Inc. (MDGL)
NASDAQ: MDGL · Pharmaceutical Preparations · West Conshohocken, PA
Our rating: Positive
Positive reaffirmed at $400.43, moderate conviction, November 4, 2026.
Breaks if: The Positive call weakens if Rezdiffra's year-over-year revenue growth rate — which ran at 432% through the most recent filing — falls below 60% in either of the next two quarterly reports, signaling the commercial ramp is plateauing faster than a 9.7x revenue multiple can tolerate. It also weakens if the annualized net loss run-rate widens above $350M in either of those same two prints, indicating the cost structure is not scaling with revenue. On the upside, the call would become Cautious if a competing MASH therapy gains broad formulary parity and new-to-brand prescription share for Rezdiffra stops growing for two consecutive quarters.
Key figures
| Market value | $8.8B |
|---|---|
| Revenue, last 12 months | $1.4B |
| Net income, last 12 months | −$155M |
| Free cash flow, last 12 months | −$169M |
| Price to earnings | n/a |
| Free cash flow yield | −1.9% |
| Dividend yield | 0.0% |
| Operating margin | −10.7% |
| Return on equity | −24.8% |
| Beta to the S&P 500 | 0.68 |
| Volatility, annualized | 50.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $431M | 50.1% | $1.83 | $117M |
| June 30, 2026 | $364M | 71.2% | $-1.99 | $19M |
| March 31, 2026 | $311M | 126.8% | $-3.25 | −$171M |
| December 31, 2025 | $321M | 210.8% | $-2.03 | −$133M |
| September 30, 2025 | $287M | 362.0% | $-4.01 | $79M |
| June 30, 2025 | $213M | 1353.8% | $-1.50 | −$47M |
| March 31, 2025 | $137M | n/a | $-2.61 | −$89M |
| December 31, 2024 | $103M | n/a | $2.00 | −$105M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.69B: Claude 8%, Gemini 25%, Mistral 15%
- Diluted earnings per share are above zero: Claude 62%, Gemini 75%, Mistral 65%
- Free cash flow for the quarter is above zero: Claude 57%, Gemini 70%, Mistral 75%
10 ledger entries and 83 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.